Home LiteratureArticle Details
PMID: 6424447 Published · ppublish English Journal Article

Replacement therapy with modified immunoglobulin G in burn patients: preliminary kinetic studies.

The American journal of medicine ·Vol. 76 ·No. 3A ·1984-03-30 ·Pages 175-80

Shirani KZ, Vaughan GM, McManus AT, Amy BW, McManus WF, Pruitt BA, Mason AD

Abstract

Suppression of serum immunoglobulin G for periods ranging from days to weeks following thermal injury may enhance the risk of infection in burn patients. In an initial trial, we attempted to determine whether intravenous pulses of Immunoglobulin G (IgG) will establish and maintain normal serum IgG concentrations in this interval. The levels of endogeneous serum IgG in eight control patients, mean total burn size 45 percent body surface area (no IgG infusions), were measured by radial immunodiffusion on various postburn days. Commercially available reduced alkylated IgG (5 percent Gamimune, Cutter Biological, Berkeley, California) was infused in doses of 500 mg/kg twice per week in four patients (total burn size 32 percent) and once per week in five patients (total burn size 47 percent), beginning during the first postburn week. Circulating IgG was measured prior to each infusion and at three postinfusion times: (1) 15 minutes (peak), (2) one day, and (3) either day 3, 4, or 6. Surgery or blood transfusions prior to one of these time points invalidated kinetic analysis of some infusions. Exponential two-point decay constants for total serum IgG after each of 24 infusions were calculated separately for early (day 0-1) and later (day 1-3 or 1-4) postinfusion intervals and assessed by stepwise regression analysis to determine sources of variation in decay. Early decay was seen to be faster with larger burn size after accounting for variation of decay with preinfusion and peak IgG values. Later decay was not related to burn size. Maltose, a constituent of the IgG preparation, was detectable in serum for only four to eight hours after each infusion and may have contributed to a 20 percent increase in total serum glucose between four and eight hours postinfusion. Mean serum IgG in patients given infusions twice weekly was in the normal range after one infusion, about a week earlier than in untreated patients. Such infusions maintained normal IgG levels.

MeSH Terms
Agammaglobulinemia/etiology,therapy Blood Glucose/metabolism Burns/complications,surgery,therapy Half-Life Humans Immunization, Passive Immunoglobulin G/administration & dosage,analogs & derivatives,metabolism Immunoglobulins, Intravenous Kinetics Maltose/blood Transfusion Reaction
Chemicals
Blood Glucose Immunoglobulin G Immunoglobulins, Intravenous Maltose
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Shirani K Z
Vaughan G M
McManus A T
Amy B W
McManus W F
Pruitt B A
Mason A D
Article Info
Journal
The American journal of medicine
Abbr.
Am J Med
ISSN
0002-9343
Published
1984-03-30
Pages
175-80
Language
English
Region
United States
NLM ID
0267200
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com